A diagnosis of progressive myoclonic ataxia guided by blood biomarkers
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 94, 124-126
Abstract
No abstract availableKeywords
Funding Information
- Université Toulouse III - Paul Sabatier
- Institut National de la Santé et de la Recherche Médicale
This publication has 8 references indexed in Scilit:
- Progressive myoclonus epilepsy without renal failure in a Chinese family with a novel mutation in SCARB2 gene and literature reviewSeizure: European Journal of Epilepsy, 2018
- SCARB2/LIMP2 deficiency in action myoclonus‐renal failure syndromeEpileptic Disorders, 2016
- Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysisJournal of Lipid Research, 2014
- A new SCARB2 mutation in a patient with progressive myoclonus ataxia without renal failureMovement Disorders, 2013
- A case of severe hearing loss in action myoclonus renal failure syndrome resulting from mutation in SCARB2Movement Disorders, 2012
- A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndromeHuman Molecular Genetics, 2008
- Array-Based Gene Discovery with Three Unrelated Subjects Shows SCARB2/LIMP-2 Deficiency Causes Myoclonus Epilepsy and GlomerulosclerosisThe American Journal of Human Genetics, 2008
- LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-GlucocerebrosidaseCell, 2007